CA3003603A1 - Mesenchymal stem cell-derived exosomes and their uses - Google Patents

Mesenchymal stem cell-derived exosomes and their uses Download PDF

Info

Publication number
CA3003603A1
CA3003603A1 CA3003603A CA3003603A CA3003603A1 CA 3003603 A1 CA3003603 A1 CA 3003603A1 CA 3003603 A CA3003603 A CA 3003603A CA 3003603 A CA3003603 A CA 3003603A CA 3003603 A1 CA3003603 A1 CA 3003603A1
Authority
CA
Canada
Prior art keywords
exosomes
exosome
tgf
particular embodiment
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3003603A
Other languages
English (en)
French (fr)
Inventor
Olga De La Rosa
Eleuterio Lombardo
Wilfried Dalemans
Javier Garcia Casado
Rebeca BLAZQUEZ DURAN
Francisco Miguel Sanchez Margallo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Tigenix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix SA filed Critical Tigenix SA
Publication of CA3003603A1 publication Critical patent/CA3003603A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3003603A 2015-11-02 2016-11-02 Mesenchymal stem cell-derived exosomes and their uses Pending CA3003603A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/929,578 US20170121685A1 (en) 2015-11-02 2015-11-02 Mesenchymal stem cell-derived exosomes and their uses
US14/929,578 2015-11-02
PCT/EP2016/076462 WO2017076924A1 (en) 2015-11-02 2016-11-02 Mesenchymal stem cell-derived exosomes and their uses

Publications (1)

Publication Number Publication Date
CA3003603A1 true CA3003603A1 (en) 2017-05-11

Family

ID=57517849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003603A Pending CA3003603A1 (en) 2015-11-02 2016-11-02 Mesenchymal stem cell-derived exosomes and their uses

Country Status (7)

Country Link
US (1) US20170121685A1 (https=)
EP (1) EP3371298A1 (https=)
JP (1) JP7069011B2 (https=)
CA (1) CA3003603A1 (https=)
HK (1) HK1254948A1 (https=)
IL (1) IL259147B (https=)
WO (1) WO2017076924A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9919011B2 (en) * 2014-03-18 2018-03-20 Samsung Life Public Welfare Foundation Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome
KR20190003316A (ko) * 2017-06-30 2019-01-09 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀 및/또는 세포외 소포체를 유효성분으로 포함하는 조성물의 피부염 개선 용도
FR3068361B1 (fr) 2017-06-30 2021-10-15 Univ Paris Diderot Paris 7 Systeme fluidique de production de vesicules extracellulaires et procede associe
KR20190011213A (ko) * 2017-07-24 2019-02-01 한양대학교 에리카산학협력단 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 골다공증 예방 또는 치료용 조성물
US11766402B2 (en) 2017-11-16 2023-09-26 Board Of Regents, The University Of Texas System Methods for production of MSC-derived exosomes
WO2019105082A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Galunisertib的晶型及其制备方法和用途
US20210161967A1 (en) * 2017-12-06 2021-06-03 Fondazione Irccs "Ca' Granda - Ospedale Maggiore Policlinico" Extracellular vesicles and uses thereof
US12257266B2 (en) 2018-03-02 2025-03-25 The Regents Of The University Of California Stem cell-derived exosomes for the treatment of corneal scarring
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
JP2021526556A (ja) 2018-05-30 2021-10-07 ダイレクト バイオロジクス エルエルシー 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法
CN108865985A (zh) * 2018-06-22 2018-11-23 山东省职业卫生与职业病防治研究院 一种干细胞源外泌体干预上皮-间质转化的方法
CN109161526A (zh) * 2018-10-12 2019-01-08 希瑞干细胞科技有限公司 一种绒毛膜间充质干细胞复苏培养基
BR112021015549A2 (pt) 2019-02-07 2021-10-26 Direct Biologics Llc Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes
EP3927317A4 (en) * 2019-02-19 2022-08-10 Direct Biologics, LLC ACELLULAR INTRAVENOUS INFUSION WITH GROWTH FACTORS FROM MESENCHYMAL STEM CELLS AND EXOSOMES
US12350293B2 (en) 2019-03-08 2025-07-08 Niigata University Induction method for macrophage, anti-inflammatory macrophage-inducing agent, and pharmaceutical composition
KR102132457B1 (ko) * 2019-05-10 2020-07-09 주식회사 바이오솔루션 세포외 소포를 고농도로 배양하기 위한 세포 배양배지 및 상기 세포 배양배지를 이용한 세포외 소포 고 함유 조건화 배양액의 제조방법
CN110184235B (zh) * 2019-05-21 2021-03-02 葛楠 一种adsc外泌体及其制备方法与应用
CN118147051A (zh) * 2019-06-10 2024-06-07 布瑞克斯奥根株式会社 用于促进干细胞来源外泌体产生和增加干性的包含白藜芦醇的组合物
CA3146433A1 (en) 2019-07-18 2021-01-21 Direct Biologics Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
CN110946876A (zh) * 2019-10-28 2020-04-03 天津市康婷生物工程集团有限公司 间充质干细胞外泌体制剂在治疗斑秃中的应用
US12590310B2 (en) 2020-04-22 2026-03-31 Direct Biologics, Llc Methods and compositions for treating inflammatory conditions associated with infectious disease
KR102319735B1 (ko) * 2020-04-28 2021-11-01 건국대학교 산학협력단 3차원 배양된 줄기세포로부터 세포외 소포체를 제조하는 방법
WO2021251616A1 (ko) * 2020-06-10 2021-12-16 재단법인 대구경북첨단의료산업진흥재단 고양이과 동물 중간엽 줄기세포 유래 엑소좀을 포함하는 조성물 및 이를 이용한 염증질환 치료방법
JP2023537204A (ja) * 2020-07-09 2023-08-31 エクソ バイオロジクス エスアー 間葉系ストローマ細胞由来の細胞外小胞（ｅｖ）および前記ｅｖを得るための方法
CN111849882A (zh) * 2020-07-17 2020-10-30 尧舜泽生物医药(南京)有限公司 间充质干细胞外泌体及其制备方法和应用
CN111944747A (zh) * 2020-08-14 2020-11-17 福建医科大学附属协和医院 一种用于治疗心肌梗死的人脂肪间充质干细胞外泌体及其用途
EP4212163A4 (en) 2020-09-08 2024-09-18 Dexon Pharmaceuticals Inc. CYTOKINE STORM INHIBITOR, METHOD FOR USING CYTOKINE STORM INHIBITOR, AND METHOD FOR SCREENING CYTOKINE INHIBITOR
WO2022080461A1 (ja) * 2020-10-16 2022-04-21 富士フイルム和光純薬株式会社 細胞外小胞の産生用培地、培地キット、添加剤及び細胞外小胞の産生方法
CN116888126B (zh) * 2020-12-15 2026-03-17 北京原基华毅生物科技有限公司 一种酪蛋白激酶抑制剂的化合物
CN115029317B (zh) * 2021-02-23 2025-10-28 赛浦生物科技(长春)有限公司 用于过敏性鼻炎的鼻喷雾剂及制备方法
CN112915105B (zh) * 2021-03-12 2024-07-19 上海市第六人民医院 间充质干细胞分泌的小细胞外囊泡在制备治疗cp/cpps的药物上的应用
CN112961240B (zh) * 2021-04-06 2022-07-05 明济生物制药（北京）有限公司 一种靶向TGF-β1的单克隆抗体及其与间充质干细胞外泌体的联合应用
CN113174363B (zh) * 2021-04-21 2023-05-30 天晴干细胞股份有限公司 用于促进iPSC分化为胰岛素分泌细胞的混合物及其制备方法
CN113846047A (zh) * 2021-06-22 2021-12-28 姜海涛 一种肾靶向载药外泌体及应用和治疗肾脏疾病药物
CN114164172A (zh) * 2021-08-27 2022-03-11 广州百暨基因科技有限公司 间充质干细胞外泌体的制备方法
CN113930393A (zh) * 2021-09-27 2022-01-14 兰州大学 一种脐带干细胞来源外泌体的提取及水凝胶的制备方法
CN113862220B (zh) * 2021-11-05 2024-02-13 杭州隽和生物医药有限公司 间充质干细胞外泌体的制备及其应用
CN114540268B (zh) * 2022-01-05 2024-07-23 陕西微泌生物科技有限公司 一种基于超纯固膜技术的植物外泌体复合物的制备方法
MX2024010560A (es) * 2022-02-28 2024-09-06 Jlm Exograde Llc Metodo para enriquecer celulas muse, y obtener exosomas, microvesiculas o el secretoma a partir de las mismas.
CN114591901B (zh) * 2022-03-24 2023-11-24 和携科技有限公司 动物脐带间充质干细胞外泌体提取方法
CN114699550A (zh) * 2022-03-29 2022-07-05 湖南有美生物科技有限公司 一种含绿茶外泌体的抗hpv功能性妇科敷料及其制备方法
JP7598150B2 (ja) * 2022-03-30 2024-12-11 株式会社山田養蜂場本社 エクソソーム分泌促進剤
CN115025288B (zh) * 2022-06-17 2023-06-13 中南大学湘雅医院 一种外泌体水凝胶混合体系及其制备方法
JP7220938B1 (ja) 2022-09-28 2023-02-13 パナジー株式会社 微小粒子、ｎｋ細胞活性化剤、ｎｋ細胞の培養方法、活性化ｎｋ細胞の製造方法およびｎｋ細胞の活性化方法
CN115537390B (zh) * 2022-10-28 2025-02-18 山东医科元多能干细胞生物工程有限公司 一种干细胞外泌体及旁分泌活性大分子连续化生产方法
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
GB2388189B (en) 2002-04-29 2006-01-11 Robert Jeffrey Geddes Carr Optical detection and analysis of particles
ES2304069B1 (es) 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
CN102014934B (zh) * 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
EP2663316A2 (en) * 2011-01-12 2013-11-20 TiGenix, S.A.U. Adipose-derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases
SG11201406336YA (en) * 2012-04-03 2014-11-27 Reneuron Ltd Stem cell microparticles

Also Published As

Publication number Publication date
EP3371298A1 (en) 2018-09-12
IL259147B (en) 2022-07-01
JP7069011B2 (ja) 2022-05-17
HK1254948A1 (zh) 2019-08-02
US20170121685A1 (en) 2017-05-04
WO2017076924A9 (en) 2017-07-27
JP2018531979A (ja) 2018-11-01
WO2017076924A1 (en) 2017-05-11
IL259147A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CA3003603A1 (en) Mesenchymal stem cell-derived exosomes and their uses
US20170119682A1 (en) Mesenchymal stem cell-derived exosomes and their uses
AU2023203680B2 (en) Induction medium and methods for stem cell culture and therapy
AU2024227344A1 (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
US11478511B2 (en) Lymphocyte biomarkers for determining the clinical response to cell therapy
JP2024109782A (ja) 副甲状腺ホルモン１型受容体を発現する細胞およびその使用
US11857575B2 (en) Mesenchymal stem cell-derived exosomes and their uses
Alfar et al. Selective reprogramming of regulatory T cells in solid tumors can strongly enhance or inhibit tumor growth
US10746729B2 (en) Biomarkers for determining the clinical response to cell therapy
Tessier Isolation, immunophenotyping and lymphocyte suppressive properties of equine cord blood-derived mesenchymal stromal cells
HK40019421A (en) Lymphocyte biomarkers for determining the clinical response to cell therapy
HK1219775B (en) Lymphocyte biomarkers for determining the clinical response to cell therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210720

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20240820

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241023

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241023

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250528

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250528

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022